Purpose of Review Hypoglycemia is the most common and often treatment-limiting serious adverse effect of diabetes therapy. Despite being potentially preventable, hypoglycemia in type 2 diabetes incurs substantial personal and societal burden. We review the epidemiology of hypoglycemia in type 2 diabetes, discuss key risk factors, and introduce potential prevention strategies. Recent Findings Reported rates of hypoglycemia in type 2 diabetes vary widely as there is marked heterogeneity in how hypoglycemia is defined, measured, and reported. In randomized controlled trials, rates of severe hypoglycemia ranged from 0.7 to 12 per 100 person-years. In observational studies, hospitalizations or emergency department visits for hypoglycemia were experienced by 0.2 (patients treated without insulin or sulfonylurea) to 2.0 (insulin or sulfonylurea users) per 100 person-years. Patient-reported hypoglycemia is much more common. Over the course of 6 months, 1-4% non-insulin users reported need for medical attention for hypoglycemia; 1-17%, need for any assistance; and 46-58%, any hypoglycemia symptoms. Similarly, over a 12-month period, 4-17% of insulin-treated patients reported needing assistance and 37-64% experienced any hypoglycemic symptoms. Hypoglycemia is most common among older patients with multiple or advanced comorbidities, patients with long diabetes duration, or patients with a prior history of hypoglycemia. Insulin and sulfonylurea use, food insecurity, and fasting also increase hypoglycemia risk. Clinical decision support tools may help identify at-risk patients. Prospective trials of efforts to reduce hypoglycemia risk are needed, and there is emerging evidence supporting multidisciplinary interventions including treatment de-intensification, use of diabetes technologies, diabetes self-management, and social support. Summary Hypoglycemia among patients with type 2 diabetes is common. Patient-centered multidisciplinary care may help proactively identify at-risk patients and address the multiplicity of factors contributing to hypoglycemia occurrence.
Introduction
Diabetes mellitus is one of the most common and increasing chronic health conditions in the USA and around the world, affecting an estimated 30.2 million (12.2%) U.S. adults [1] and 422 million (8.4%) adults worldwide [2, 3] . Most, approximately 95%, have type 2 diabetes [1] . Diabetes is a major cause of blindness, kidney failure, heart attacks, strokes, and lower extremity amputations and is the seventh leading cause of death in the USA and around the world [1, 2] . To reduce these risks, diabetes management has prioritized lowering blood glucose levels through lifestyle modifications and glucose-lowering medications. In the USA, 23 million (9.3%) adults have been diagnosed with diabetes (the remainder are undiagnosed), and 83% of them are treated with glucoselowering medications [1] . However, glucose-lowering pharmacotherapy can lead to iatrogenic hypoglycemia, the most common and often treatment-limiting adverse effect of diabetes therapy [4] . While commonly accepted by patients and their healthcare providers as an inevitable consequence of preventing long-term diabetes complications, hypoglycemia is increasingly recognized an important and potentially preventable cause of morbidity, mortality, high costs, diminished productivity, and impaired quality of life [5•, 6, 7, 8 •, 9•, 10•, [11] [12] [13] [14] .
Real-world data on hypoglycemia rates and risk factors are necessary to inform patients and healthcare providers about the benefits and potential harms of glucose-lowering therapies, facilitate shared decision making, and guide clinical practice. In this review, we discuss the epidemiology of hypoglycemia among adults with type 2 diabetes as revealed by studies conducted in diverse clinical settings and patient populations. We focus specifically on type 2 diabetes because the risk of hypoglycemia in this population is more heterogeneous, treatment-dependent, and ultimately less inevitable than in type 1 diabetes. We conclude by offering insights into some of the risk factors for hypoglycemia and introducing potential prevention strategies.
Defining Hypoglycemia
An important barrier to quantifying and understanding the burden of hypoglycemia is the marked heterogeneity in how it is defined, documented, and ascertained. Since 2005, the American Diabetes Association (ADA) has defined confirmed hypoglycemia as symptomatic or asymptomatic blood glucose ≤ 70 mg/dL (3.9 mmol/L), probable hypoglycemia as symptoms typical of hypoglycemia in the absence of blood glucose measurements, and relative hypoglycemia as typical symptoms accompanied by blood glucose > 70 mg/dL (3.9 mmol/L) [15] . Severe hypoglycemia was defined as hypoglycemia requiring assistance of another person for management and symptom recovery after treatment [15] . In 2013, the ADA began to explicitly recommend that providers routinely ask at-risk patients about symptomatic and asymptomatic hypoglycemia [16] , thereby acknowledging the importance of patient-reported events. In 2017, the ADA reclassified blood glucose ≤ 70 mg/dL (3.9 mmol/L) as a hypoglycemia alert value warranting treatment with fast-acting carbohydrate and adjustment of glucose-lowering therapy, added the category of clinically significant hypoglycemia with blood glucose < 54 mg/dL (3.0 mmol/L), and reaffirmed severe hypoglycemia as the presence of severe cognitive impairment requiring external assistance for recovery irrespective of the glucose level [17, 18] . However, these definitions are difficult to operationalize in population-based and clinical research. Most hypoglycemic events occur outside the confines of the healthcare system [19, 20, 21 •], and we lack efficient mechanisms to detect and document such events. Indeed, while low blood glucose values are captured by selfmonitoring of blood glucose and continuous glucose monitors as part of routine or symptom-responsive testing, this data is not routinely incorporated into the electronic health record. As a result, hypoglycemic events occurring in the real-world setting and outside of prospectively defined research studies or registries cannot be easily or consistently detected.
Research studies generally focus on either documented hypoglycemia (confirmed by a laboratory result, a patientmeasured glucose value that is directly visible to the research or clinical team, or a clinical encounter with the diagnosis of hypoglycemia) or patient-reported hypoglycemia (reported by the patient without explicit confirmation by laboratory data). In many research studies, hypoglycemia is reported without a clear definition of how it was measured or defined. The type of hypoglycemia reported is typically contingent on study design and data source. Cross-sectional (e.g., survey or interview) studies commonly assess patient-reported events, whereas retrospective studies using administrative or electronic health record data focus on healthcare utilization events with the diagnosis codes of hypoglycemia. While there are validated claims-based algorithms to identify hypoglycemic encounters using ICD-9 [22] and ICD-10 [23] codes, studies vary widely in their choice of diagnosis codes and types of encounters (e.g., ambulatory visits, emergency department visits, hospitalizations) used to capture events. Some retrospective and many prospective studies also report hypoglycemic events confirmed by laboratory results, which can be patient reported or documented in the electronic health record, with qualifying glucose values ranging between 36 mg/dL (2.0 mmol/L) and 70 mg/dL (3.9 mmol/L).
All of these approaches to identifying hypoglycemic events have limitations. Self-report of hypoglycemia is affected by accuracy of patient recall, which can be poor, particularly for non-severe events [24] . It is further contingent on the patient's ability to recognize hypoglycemia when it occurs, which is limited by impaired hypoglycemia awareness, and to correctly differentiate them from symptoms unrelated to hypoglycemia. On the other hand, exclusive reliance on documented low blood glucose values will fail to identify events during which patients did not, or could not, measure their blood glucose. Furthermore, approximately 95% of hypoglycemic events are managed outside the healthcare system, by either the patient or caregivers or emergency medical services [19, 20, 21•] . These events do not precipitate a clinical encounter or billing claim and are therefore missed by methods that rely on administrative or electronic health record data. The probability that a hypoglycemic event is brought to medical attention is confounded by multiple factors including patient access to healthcare, availability of resources (e.g., food, medications and third-party assistance) to manage hypoglycemia, and the ability to recognize and effectively treat hypoglycemic events when they occur. For example, in a study of ambulance calls for hypoglycemia, 13.5% of patients with hypoglycemia (blood glucose < 60 mg/dL [3.3 mmol/L]) were managed on the scene without transport to the emergency department [25] . Patients brought to the emergency department were more likely to be older, reside in skilled nursing or assisted living facilities, or have altered consciousness or weakness (both potential signs of frailty) [25] . Thus, all reports of hypoglycemia need to be considered in the context of the methodology used to identify and measure these events.
Frequency of Hypoglycemia in Randomized Controlled Trials
Severe hypoglycemia occurred rarely in the two landmark randomized controlled trials conducted among patients with newly diagnosed type 2 diabetes or prediabetes. The UK Prospective Diabetes Study (UKPDS) of intensive glucoselowering therapy in type 2 diabetes enrolled adults with newly diagnosed type 2 diabetes who had no significant microvascular or macrovascular disease between 1977 and 1991. Participants were treated with metformin, sulfonylurea, or insulin to maintain fasting plasma glucose < 108 mg/dL (6 mmol/L) or received standard treatment of diet alone as long as fasting plasma glucose remained < 270 mg/dL (15 mmol/L) and participants were asymptomatic [26, 27] . Severe hypoglycemia, defined by need for third-party assistance, occurred each year, on average, in 0.1/100 patients treated with diet, 0.4-0.6/100 patients treated with sulfonylurea, and 2.3/100 patients treated with insulin [27] . Non-severe hypoglycemia was more common, with at least one hypoglycemic event per year experienced by 0.8/100 persons treated with diet, 1.7/100 persons treated with metformin, 7.9/100 persons treated with sulfonylurea, 21.2/100 persons treated with basal insulin, and 32.6/100 persons treated with basal plus prandial insulin [28] . More recently, the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial compared intensive glucose-lowering therapy with insulin glargine (targeting fasting plasma glucose ≤ 95 mg/dL [5.3 mmol/L]) vs. standard treatment among older patients with cardiovascular disease risk factors and either prediabetes or early type 2 diabetes [29] . The incidence rates of severe hypoglycemia requiring third-party assistance were 1.00/100 person-years in the insulin glargine group and 0.31/100 person-years in the standard treatment group [29] .
The paradigm of type 2 diabetes management began to shift a decade ago after three large randomized controlled trials of intensive glycemic control conducted among adults with long-standing type 2 diabetes at high cardiovascular disease risk did not demonstrate meaningful improvements in cardiovascular events or mortality, yet had much higher rates of hypoglycemia than both UKPDS and ORIGIN trials [30] [31] [32] [33] . In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, intensive treatment also resulted in higher cardiovascular and all-cause mortality [31] , thereby raising awareness of potential risks associated with intensive glucose-lowering therapy, polypharmacy, and overtreatment. These trials sought to lower HbA 1c much more aggressively than either UKPDS or ORIGIN, with the intensive treatment arms targeting HbA 1c levels below 6% [31, 32] or 6.5% [30] , often using multiple glucose-lowering medications. As a result, intensive treatment more than doubled the risk of hypoglycemia compared to standard treatment [30] [31] [32] . While hypoglycemia itself was not the immediate cause of excess death in these trials, it was associated with a two-to threefold increase in major macrovascular and microvascular events and all-cause mortality irrespective of the treatment arm [5••, 8•] .
The absolute rates of severe hypoglycemia observed in these trials varied widely, demonstrating how much hypoglycemia risk is contingent on patient characteristics, treatment modality, and approach to ascertainment and monitoring during the trial. In the intensive vs. standard treatment arms, rates of severe hypoglycemia were 0.7 vs. 0.4/100 patient-years in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial (defined by symptoms or blood glucose < 50 mg/dL [2.8 mmol/ L] resulting in transient central nervous system dysfunction and need for any third-party assistance) [30] , 3.1 vs. 1.0/100 patient-years in ACCORD (defined by requiring medical assistance) [31] , and 12 vs. 4/100 patient-years in the Veterans Affairs Diabetes Trial (VADT; defined by impaired or complete loss of consciousness) [32] . Non-severe hypoglycemia was much more common with 120 vs. 90 events/100 patientyears in ADVANCE [30] , while rates of any hypoglycemia in VADT were 1566 vs. 432/100 patient-years, in the intensive vs. standard treatment arms, respectively [32] .
More recent large randomized controlled trials of glucoselowering therapies have focused primarily on the cardiovascular safety of newly approved glucose-lowering medications rather than intensive glycemic control. These trials include EMPA-REG OUTCOME (empagliflozin) [34] , CANVAS (canagliflozin) [35] , LEADER (liraglutide) [36] , SAVOR-TIMI 53 (saxagliptin) [37] , TECOS (sitagliptin) [38] , EXAMINE (alogliptin) [39] , ELIXA (lixisenatide) [40] , SUSTAIN-6 (semaglutide) [41] , and DEVOTE (insulin degludec) [42] . Most patients had baseline HbA 1c above 8% (except TECOS and ELIXA, where baseline HbA 1c was 7.2% [38] and 7.6% [40] , respectively), and patients were treated to standard HbA 1c targets in all treatment arms; differences in HbA 1c levels achieved with study drugs vs. placebo were less than 0.5%. Hypoglycemia was infrequent in these trials, though there was variability in how hypoglycemia was reported (e.g., the percent of patients with at least one hypoglycemic event during the study period vs. annualized event rates). Severe hypoglycemia requiring third-party assistance occurred in 1.3% of empagliflozin-treated patients (vs. 1.5% in the placebo group; median 3.1 years of observation) [34] , 2.4% of liraglutide-treated patients (vs. 3.3% in the placebo group; median 3.8 years of observation) [36] , 2.1% of saxagliptin-treated patients (vs. 1.7% in the placebo group; median 2.1 years of observation) [37] , and 0.7% of alogliptin-treated patients (vs. 0.6% in the placebo group; median 1.5 years of observation) [39] . In the TECOS trial, severe hypoglycemia occurred at the rate of 0.8/100 person-years in the sitagliptin group and 0.7/100 person-years in the placebo group [38] . Non-severe hypoglycemia with blood glucose ≤ 54 mg/dL (3.0 mmol/L) occurred in 14.2% of saxagliptintreated patients (vs. 12.5% in the placebo group) [37] and < 70 mg/dL (3.9 mmol/L) in 27.9% of empagliflozin-treated patients (vs. 27.8% in the placebo group) [34] . Any hypoglycemia occurred in 6.7% of alogliptin-treated patients (vs. 6.5% in the placebo group) [39] and 21.7-23.1% of semaglutidetreated patients (vs. 21-21.5% in the placebo group; median 2.1 years of observation) [41] . In the CANVAS trial, rates of any hypoglycemia were 5.0/100 person-years in the canagliflozin group and 4.6/100 person-years in the placebo group [35] . Finally, in the DEVOTE trial (the only cardiovascular outcome trial of an insulin agent), rates of severe hypoglycemia were 3.7/100 person-years in the insulin degludec group and 6.3/100 person-years in the insulin glargine group [42] .
Results from trials may not immediately generalize to realworld practice. Large randomized trials often select motivated patients who are adherent to their recommended treatments, are less likely to experience socioeconomic barriers to care, are closely monitored, and may have their treatment regimens promptly adjusted in the event of hypoglycemia. None of the studies discussed above included patients with history of severe hypoglycemia, poor health status, or major noncardiovascular comorbidities. As a result, the rates and nature of hypoglycemia reported in trials likely differ substantially from real-world practice [43•] .
Frequency of Hypoglycemia in Real-World Studies
Iatrogenic hypoglycemia is one of the most common adverse drug events requiring emergency department care or hospitalization [44] . The Centers for Disease Control and Prevention estimates that there were 245,000 emergency department visits for hypoglycemia in 2014, or 1.12 visit/100 personyears, exceeding the number of hyperglycemic crises managed in the emergency department (0.95 event/100 personyears) [1] . Between 2007 and 2009, insulin and oral glucose-lowering medications were implicated in nearly 14% and 10.7% of emergent hospitalizations among diabetes patients ≥ 65 years, respectively [44] , though hypoglycemia was not necessarily the primary reason for admission. In a claims-based study of commercially insured and Medicare Advantage beneficiaries across the USA, hypoglycemia was the primary reason for hospitalization among 1.2% of 594,146 hospitalized adults with diabetes between 2009 and 2014 [45•] . However, these estimates, which include patients with type 1 and type 2 diabetes, likely represent a small fraction of hypoglycemic events, as hypoglycemia rarely necessitates emergency care and even less often culminates in hospital admission [19, 20, 21•] .
When patients were asked about their experience of severe hypoglycemia, the rate of self-reported events varied widely. Multiple studies have assessed the rates of self-reported hypoglycemia, most often during the preceding 6-month period, among non-insulin-treated patients with type 2 diabetes. Rates of severe hypoglycemia, defined by requiring thirdparty assistance, were highly variable, ranging from 1% (questionnaire completed by 412 patients in Sweden; mean age 69 years, 71% with diabetes duration > 7 years, mean HbA 1c 6.3%, all on metformin/sulfonylurea combination therapy) [46] , 9% (questionnaire completed by 392 patients in Germany; mean age 62.7 years, 60.3% with diabetes duration > 7 years, HbA 1c 7.2%, all on metformin/sulfonylurea combination therapy) [47] , 12% (questionnaire completed by 2257 patients in China, Korea, Taiwan, Malaysia, and Thailand; mean age 58.7 years, HbA 1c 7.5%, 13.9% on metformin monotherapy and 46% using sulfonylureas) [48] , 13% (Internet survey completed by 1984 non-insulin-treated patients in the USA; mean age 58.1 years, diabetes duration 7.3 years, 50% treated with sulfonylurea) [49] , and 17% (postal survey completed by 326 patients with type 2 diabetes in the USA; mean age 69.3 years, diabetes duration 15.7 years, HbA 1c 7.4%, 66% insulin treated) [14] . In the same studies, severe hypoglycemia requiring medical assistance was reported by 1% [46] , 6% [47] , 8% [48] , and 4% [49] of respondents. Non-severe events were much more frequent. Mild events, defined by symptoms causing little disruption to patients' activities, were reported by 51% [47] , 58% [48] , and 46% [49] of participants. Similarly, moderate severity events, defined by symptoms causing disruption but self-managed, were reported by 17% [46] , 46% [47] , 22% [48] , and 37% [49] .
Patients treated with insulin have higher self-reported rates of hypoglycemia. Studies conducted in this population commonly asked patients treated with insulin for ≥ 1 year about hypoglycemic events in the preceding 12 months. Selfreported severe hypoglycemia, defined by requiring thirdparty assistance, was reported by 4% (interview of 1667 patients in the Netherlands; mean age 67.2 years, diabetes duration 11.5 years, using insulin for 4.6 years) [50] , 15% (interview of 215 patients in Scotland; mean age 68 years, HbA 1c 8.6%, diabetes duration 13 years, using insulin for 4 years) [51] , and 17% (survey completed by 401 patients in Denmark; mean age 66 years, HbA 1c 8.3%, diabetes duration 15 years, using insulin for 7 years) [52] of patients. Once again, nonsevere hypoglycemic events were more common, reported by 37% [50] and 64% [51] of patients in these studies.
More recently, the InHypo-DM Study of patient-reported hypoglycemia examined hypoglycemia rates among patients treated with insulin and/or insulin secretagogues. An online survey was completed by 458 patients with self-identified type 2 diabetes (mean age 53.4 years, diabetes duration 10.0 years, HbA 1c 7.1%) who reported taking insulin (34.7%), insulin secretagogues (47.4%), or both (17.9%); it included questions about non-severe (symptoms of hypoglycemia managed by the patient) and severe (symptoms requiring any third-party assistance) hypoglycemic events in the preceding 30 days and 12 months, respectively. Non-severe hypoglycemia was reported by 54% of patients (12.1 events per person-year), and severe hypoglycemia was reported by 38% (2.5 events per person-year) [53] .
Reliability of self-reported measures of hypoglycemia is contingent on confidence in patients' hypoglycemia awareness, willingness to report events, and ability to differentiate true hypoglycemia from pseudo-hypoglycemia. In a study of 6273 insulin-treated adults with type 2 diabetes (median age 58 years, diabetes duration 12 years, HbA 1c 8.6%, using insulin for 5 years), 48.1% of patients had blood glucose < 3.1 mmol/L (56 mg/dL) over a 4-week period (1.6 event/patient/month). However, analysis of continuous glucose monitor data revealed that in fact 95.3% had experienced episodes of hypoglycemia (2.4 events/patient/month). Furthermore, just 1.7% were hospitalized for hypoglycemia during the 4-week period (0.026 event/patient/month) [54••] , reinforcing the small fraction of hypoglycemic events captured by hospitalization encounters.
Continuous glucose monitoring detects substantially more hypoglycemic events than identified and reported by patients. This was demonstrated in the continuous glucose monitor sub-study of the Treating to Target in Type 2 Diabetes Trial (4-T), wherein 106 patients with insulin-dependent type 2 diabetes (mean age 61.8 years, diabetes duration 8.9 years, HbA 1c 8.5%) underwent continuous glucose monitoring. During the 3-day study period, 10% reported hypoglycemia with glucometer glucose < 3.1 mmol/L (56 mg/dL), yet continuous glucose monitor data showed that 42% had glucose ≤ 3.0 mmol/L (54 mg/dL) and 18% had glucose ≤ 2.2 mmol/L (40 mg/dL) [55] . In another study of 108 patients with type 2 diabetes (both insulin and non-insulin treated), continuous glucose monitoring detected glucose < 70 mg/dL (3.9 mmol/ L) in 49.1% of participants over 5 days (1.74 episode/patient per 5 days); 75% of those with hypoglycemia had at least one asymptomatic event [56] . Despite its incompleteness, glucometer data is still informative, particularly as continuous glucose monitors are used infrequently by patients with type 2 diabetes. In a study of 165 insulin-treated adults with type 2 diabetes (mean age 67, diabetes duration 18 years, HbA 1c 7.6%), an electronic diabetes management system was retrospectively used to capture patients' home glucometer data at the time of clinical encounters. Over a 3-month period, 19% of patients had episodes with glucose ≤ 45 mg/dL (2.5 mmol/L) and 82% with glucose ≤ 70 mg/dL (3.9 mmol/L), corresponding to annualized rates of 2.9 and 37 events/person-year, respectively [57] .
Clinicians are often unaware of their patients' hypoglycemic events, potentially due to patient reluctance to report events and lack of direct questioning about hypoglycemia in between and during clinical encounters. Patients may underreport hypoglycemia due to fear of repercussions such as loss of driving privileges [58] . In a Japanese Web survey of 230 insulin-treated adults with type 2 diabetes (mean age 55 years, diabetes duration 15 years), 90% of respondents reported at least one episode of non-severe daytime hypoglycemia and 34% reported at least one episode of non-severe nighttime hypoglycemia over the prior 3 months. However, only 60% of patients experiencing daytime hypoglycemia and 42% experiencing nighttime hypoglycemia had notified their healthcare provider [59] . In another online survey of 3042 insulin-treated adults with type 2 diabetes (mean age 61 years, diabetes duration 11 years, using insulin for 5 years) in the USA, Canada, Japan, Germany, UK, and Denmark, 36% endorsed non-severe (i.e., self-treated) hypoglycemia during the preceding 30 days (3.1 events/person/30 days), but only 2% of those with hypoglycemia were seen by their healthcare provider for it, 1% emailed their healthcare provider, 1% saw a diabetes specialist, and fewer than 1% were evaluated in the emergency department [60] . This has important research and clinical implications, because if patients do not report or discuss their hypoglycemic events with their healthcare providers, precipitating factors cannot be identified, treatment is unlikely to be modified, and future hypoglycemic events are less likely to be prevented.
Hypoglycemic events requiring emergency department care or hospitalization are, by definition, most severe, as they represent the need for the highest level of medical assistance. In a UK study of 17,604 sulfonylurea-treated patients (mean age 68 years, diabetes duration 1.6 years), there were 0.42 hospitalization/100 person-years for hypoglycemia [61] . In a more recent U.S. study of 206,435 adults with type 2 diabetes (mean age 64; 35% treated with sulfonylurea and 20% treated with insulin), the rate of emergency department visits or hospitalizations for hypoglycemia was 0.49/100 person-years [62••] . And in a German study of 29,485 sulfonylurea-treated patients (median age 71 years, diabetes duration 8.2 years), which defined severe hypoglycemia more broadly as requiring external help, causing altered mental status or seizure and/or requiring hospitalization, there were 3.9 severe hypoglycemic events/100 patient-years [63••] . In this study, severe hypoglycemia rates by treatment regimen were, per 100 patient-years, 6.7 (sulfonylurea plus insulin), 4.9 (sulfonylurea plus insulin plus other non-insulin drugs), 3.1 (sulfonylurea plus other non-insulin drugs), and 3.8 (sulfonylurea only) [63••] .
Despite the recent availability and use of new classes of glucose-lowering medications that have a lower risk of hypoglycemia (e.g., glucagon-like peptide 1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose transport protein 2 (SGLT-2) inhibitors) [64] , rates of severe hypoglycemia do not appear to be decreasing. In a claims-based study of 1.66 million U.S. commercially insured and Medicare Advantage beneficiaries with type 2 diabetes, emergency department visits and hospitalizations for hypoglycemia remained stable at 1. There is limited data regarding diabetes management and hypoglycemia among people living in long-term care facilities, despite their high clinical complexity and, presumably, hypoglycemia risk. Approximately one third of nursing home residents in the USA have diabetes [67] . In a cohort study of 200 patients aged ≥ 65 years (mean age 80 years) in two U.S. skilled nursing facilities, the majority of patients were treated with hypoglycemia-prone drugs: 71% were treated with insulin, 15.5% with insulin and non-insulin drugs, and 13.5% with only non-insulin drugs; 78% of the non-insulin drugs were sulfonylureas. During up to 30 days of observation, 38% of patients in the study experienced events with glucose < 70 mg/ dL (3.9 mmol/L; 3.4% of patient-days) and 3.5% with glucose < 40 mg/dL (2.2 mmol/L; 0.1% of patient-days) [68] . Hypoglycemia rates were similar among patients treated with insulin and non-insulin medications. Two other studies that focused on nursing home residents in the USA [69] and India [70] demonstrated comparable rates of hypoglycemia.
Risk Factors for Hypoglycemia
Precipitating events for hypoglycemia are rarely ascertained, documented, and reported in the literature. In a UK online survey of 1329 adults with type 2 diabetes (mean age 58.8 years, diabetes duration 9.6 years, HbA 1c 7.3%, 76.2% treated only with non-insulin medications), most hypoglycemic events were ascribed to dietary factors: delayed meals (29%), irregular or inadequate carbohydrates (25%), or skipped meals or snacks (20%) [71] . Other commonly cited factors were excessive physical activity (16%) and stress (13%). Medication misadventures were implicated less often; 10% of patients blamed a miscalculated insulin dose and 5% a newly started glucose-lowering medication [71] . Similar factors were cited by participants in the ACCORD trial, including delayed or missed meals (31% of patients in the intensive treatment arm and 44% of patients in the standard treatment arm), eating fewer carbohydrates than usual (26% and 25%, respectively), more or unplanned exercise (15% and 12%, respectively), use of more insulin than prescribed or usually administered (5% and 7%, respectively), and illness (4% and 3%, respectively) [72] . In the SAVOR-TIMI 53 trial of saxagliptin therapy, there was an identifiable precipitant in 47.3% of hypoglycemic events in the saxagliptin arm and 48.4% in the placebo arm, including illness (2.5% and 3.1%, respectively), overdose of hypoglycemic agent (9.8% and 7.8%, respectively), and missed meals (50.7% and 48.7%, respectively) [73] .
The risk of hypoglycemia in type 2 diabetes is influenced by many patient-and treatment-related factors (Fig. 1) . One of the strongest predictors of future hypoglycemia is history of prior hypoglycemia, both severe and non-severe [45•, 62••, 74, 75] . A large U.S. claims-based case control study of adults with type 2 diabetes found that an emergency department visit for hypoglycemia within prior 180 days increased the risk of subsequent hospitalization for hypoglycemia by 9.5-fold [76] . In a U.S. claims-based cohort study, history of an ambulatory visit for hypoglycemia increased the risk of subsequent hypoglycemia requiring emergency department or hospital care by threefold [77] . Similarly, in the prospective Fremantle Diabetes Study, the risk of ambulance use, emergency department care, or hospitalization for hypoglycemia during 6.4 years of follow-up increased more than sixfold with prior history of severe hypoglycemic events [78] .
A strong and potentially modifiable risk factor for hypoglycemia is the choice of glucose-lowering therapy, with insulin or insulin secretagogues (e.g., sulfonylureas and meglitinides) posing the highest risk [44, 65••, 66••, 74, 79, 80] . In the ORIGIN trial, the risk of severe hypoglycemia increased 2-fold with sulfonylureas and 4.5-fold with insulin [81] . In observational studies, the risk of severe hypoglycemia was increased two-to threefold with sulfonylureas [76] [77] [78] and three-to fourfold with insulin [77, 78] . The risk of hypoglycemia is highest with prolonged insulin use, as demonstrated by a UK study that prospectively quantified rates of hypoglycemia (glucose < 54 mg/dL [3.0 mmol/L]) in sulfonylurea-and insulin-treated adults over a 9-12-month observation period [82] . Rates of severe hypoglycemia requiring third-party assistance were 10/100 person-years among sulfonylurea-treated patients (mean age 60.8 years, diabetes duration 6 years, HbA 1c 7.5%) and patients treated with insulin for < 2 years (mean age 59.7 years, diabetes duration 7 years, HbA 1c 7.4%), and 70/100 person-years among patients treated with insulin > 5 years (mean age 62.4 years, diabetes duration 14.2 years, HbA 1c 7.7%). Non-severe events were more common: 192/100 person-years, 408/100 personyears, and 1020/100 person-years among patients treated with sulfonylurea, insulin < 2 years, and insulin > 5 years, respectively. At the same time, 7-day CGM detected interstitial glucose < 40 mg/dL (2.2 mmol/L) in 14% of sulfonylurea-treated patients (0.25 event/person/week), 13% of patients treated with insulin for < 2 years (0.29 event/person/week), and 26% of patients treated with insulin for > 5 years (0.73 event/person/week) [82] . In the Fremantle Diabetes Study, the risk of severe hypoglycemia requiring ambulance, emergency department, and hospital care increased by 42% with each additional year of insulin therapy [78] . Still, glucose-lowering polypharmacy in high-risk patients (e.g., the elderly or those with multiple comorbidities) can lead to hypoglycemia independent of sulfonylurea or insulin [5••, 77, 78, 83••] .
Importantly, while sulfonylurea and insulin medications do carry the highest risk of hypoglycemia, they can be used safely and should not be avoided if clinically necessary. Indeed, patients may be limited to using insulin or sulfonylurea drugs for a variety of clinical and non-clinical reasons, including intolerance or contraindication to other medications or cost considerations. Metformin is the only generic medication at low risk of hypoglycemia that is part of the World Health Organization list of essential medicines and available through low-cost generic drug programs in the USA [84] , together with human insulin and sulfonylureas. If patients do not tolerate metformin, have contraindications to its use, or require treatment intensification beyond metformin, sulfonylureas and insulin may be the only affordable treatment options.
Other commonly cited risk factors for hypoglycemia in type 2 diabetes include older age [ . Impaired hypoglycemia awareness, which affects up to 10% of insulintreated patients with type 2 diabetes, further increases the risk of hypoglycemia by nearly fivefold [90] .
Social determinants of health also contribute to hypoglycemia risk, including food insecurity [91] [92] [93] , socioeconomic deprivation, and poor health literacy [19] . A populationbased study in California, which included all adults with diabetes as it could not subset patients by diabetes type, found that hospitalizations for hypoglycemia were much more common among lower-income adults (0.27 event/100 personyears) compared to higher-income adults (0.20 event/100 person-years). Furthermore, lower-income, but not higher-income, adults experienced a 27% increase in hypoglycemia admissions in the last week of the month (period of greater food insecurity and financial hardship) compared to the first [91] . Even among commercially insured adults, patients with diabetes (once again, not subset by diabetes type) earning less than the median household income had a significantly higher rate of emergency department visits and hospitalizations for hypoglycemia than higher-income patients (0.20 event/100 person-years vs. 0.15 event/100 person-years), with the greatest probability of events during the last week of the month [94••] . There have been no studies of food insecurity exclusively in type 2 diabetes. Several studies also found an increased risk of hypoglycemia among racial/ethnic minorities, particularly African Americans [77, 85•, 86, 95, 96] , though this may be confounded by differences in access to healthcare, food insecurity, and financial burden-factors that are known to increase hypoglycemia risk yet are poorly ascertained in many research studies.
An often overlooked hypoglycemia risk factor is fasting, whether planned or unplanned. Continuing to take glucoselowering medications while fasting for medical tests or procedures can lead to hypoglycemia [97] . Patients who observe Ramadan are at increased risk of hypoglycemia while fasting, particularly when treated with insulin or sulfonylurea drugs [98] [99] [100] .
The association between HbA 1c and hypoglycemia risk is complex, partly because HbA 1c reflects the average glycemic control over a 3-month period and does not convey glycemic variability and excursions. Recent studies have suggested that low HbA 1c may predict hypoglycemia risk in type 1 but not type 2 diabetes [57] . While hypoglycemia rates were higher among patients with type 2 diabetes achieving low HbA 1c targets with intensive glucose-lowering therapy in the ADVANCE [30] , ACCORD [31] , and VADT [32] trials, these episodes may be the result of intensive treatment and polypharmacy rather than low glycemic levels themselves [5••] . In a survey of patients with diabetes, the relationship between HbA 1c and severe hypoglycemia was U shaped, and the association became less significant once other key patient-and treatment-related factors were taken into consideration (specifically, patient age, sex, comorbidities, polypharmacy, diabetes medications used, history of prior hypoglycemia) [20] . In the UKPDS trial, hypoglycemia was more common at lower HbA 1c levels among patients treated with metformin or sulfonylureas and at higher HbA 1c levels among patients treated with insulin [28] . In most studies, however, the risk of hypoglycemia increased progressively with higher, not lower, HbA 1c [5••, 78, 85•] .
Preventing Hypoglycemia
Preventing hypoglycemia is a priority for patients, healthcare providers, and policy makers [101] . Diabetes agents and iatrogenic hypoglycemia are part of the U.S. Department of Health and Human Services Adverse Drug Event Action Plan. These initiatives may provide counterbalance to existing incentives and performance metrics rewarding intensive glycemic control and low HbA 1c targets. Incorporation of patient-reported outcomes into diabetes management and use of individualized glycemic targets can further raise awareness about hypoglycemia and align financial incentives with patient safety [102] .
The first step in preventing hypoglycemia is identifying patients at highest risk of these events, engaging them in conversation about contributing and/or exacerbating factors, and identifying strategies to mitigate these risks (Fig. 2) . Through shared decision making, patients and clinicians can apply scientific evidence regarding the benefits and risks of glucoselowering therapy to each patient's unique circumstance, context, and preferences for care [103] . Clinical decision support tools can facilitate this process by integrating a variety of data sources to compute an individualized hypoglycemia risk and alert providers when an intervention may be necessary [104, 105] . Ideally, clinical decision support tools would also guide interventions, signaling need to change or de-escalate glucoselowering therapy and/or make appropriate referrals [106] .
Two recently published hypoglycemia prediction models can help identify at-risk patients [ While clinical practice guidelines recommend raising glycemic targets for patients at high risk of hypoglycemia [17] , this strategy alone may not be sufficient [108•, 109] . A more effective approach may be to proactively de-intensify treatment regimens of overtreated patients [110••, 111•] . Potential overtreatment of adults with type 2 diabetes is common among patients, including older adults, with advanced kidney disease and dementia and patients with high clinical complexity [83••, 112-114] . These patients are at highest risk of hypoglycemia, yet because of their multimorbidity and limited life expectancy, they also derive less benefit from intensive ) due to limited data supporting safety and efficacy in this population [115] . Still, in clinical practice, access to these medications may be limited by financial considerations and formulary restrictions, which would need to be addressed as part of a systems-wide effort to promote safe, effective, and equitable diabetes care.
Engagement and coordination of multidisciplinary clinical teams may also improve diabetes management and reduce hypoglycemia risk (Fig. 2) . Patients experiencing or at risk of hypoglycemia may benefit from diabetes self-management education focused on glucose monitoring, medication management, recognition of precipitating events, and treatment of hypoglycemia. Training in hypoglycemia awareness, though studied primarily in patients with type 1 diabetes [116] , may benefit patients with type 2 diabetes and hypoglycemia unawareness. While continuous glucose monitoring can help patients identify asymptomatic or undetected hypoglycemic events and they are approved for patients with type 2 diabetes on the basis of lowering HbA 1c [117] , evidence for hypoglycemia reduction with continuous glucose monitoring in type 2 diabetes (in contrast to type 1 diabetes) is inconsistent [117] [118] [119] [120] [121] . Dieticians can help address hypoglycemia related to dietary miscalculations, while mental health professionals can focus on diabetes distress, fear of hypoglycemia, and treatment burden. Patients with complex treatment regimens may benefit from pharmacist engagement to identify safer, simpler, or more affordable treatment options. While pharmacist-led interventions have not been studied in relation to hypoglycemia, there is evidence for improved HbA 1c , medication adherence, and access to care [122] .
Finally, real-time integration of patient-generated glycemic data and self-reported events into the electronic health record for clinical review, followed by bidirectional flow of information between the clinical setting and the patient's home, may help identify, treat, and ultimately prevent hypoglycemic events. In a pilot study, real-time evaluation of blood glucose data obtained using a connected glucometer by a diabetes educator lowered the probability of hypoglycemia (glucose < 70 mg/dL [3.9 mmol/L]) by 18% [123] .
Provider awareness of the patient's situation is also necessary to gauge hypoglycemia risk and identify strategies to reduce it. This includes cultural practices, eating and physical activity habits, and socioeconomic realities. For instance, fasting increases the risk of hypoglycemia during a predefined time period, and proactive focused patient education and treatment modification may reduce this risk ahead of medical tests or procedures [97] and during Ramadan [124] . Community health workers show promise in improving diabetes management in immigrant groups [125, 126] , though their impact on hypoglycemia has not been assessed. Similarly, enhancing financial and social support may help lower hypoglycemia risk in vulnerable patients. In a study of commercially insured people with diabetes, the end-of-month increase in emergency department visits and hospitalizations for hypoglycemia that was likely driven by food insecurity was lessened by an increase in Supplemental Nutrition Assistance Program benefits [94••] , reinforcing access to food as an important component of diabetes management. Enhancing caregiver support and supervision can also help, particularly if patients need assistance with food preparation, medication administration, and treatment of hypoglycemia before it becomes very severe. Identifying these non-clinical factors, engaging patients and social support networks, and acknowledging the realities of each patient's situation are important aspects of patientcentered diabetes care that need to be evaluated in prospective studies and, if successful, implemented into practice.
Conclusions
Many patients with type 2 diabetes experience hypoglycemia, increasing their risk of adverse health outcomes including death, high costs, and impaired quality of life. Yet, few events are brought to medical attention or elicited by healthcare providers, which hinders identification of precipitating and contributing causes and, ultimately, prevention of future hypoglycemia. Understanding, managing, and preventing hypoglycemia is particularly important for patients with type 2 diabetes, whose risk may be lessened through the use of safer treatment regimens. Furthermore, evidence demonstrating benefits of intensive glucose-lowering therapy is weaker and less consistent for type 2 diabetes compared to type 1 diabetes, whereas the risk of hypoglycemia is often increased due to older age and higher comorbidity burden.
Prospective clinical trials focused specifically on reducing hypoglycemia among high-risk patients with type 2 diabetes are needed. There are several barriers to such trials, including heterogeneity of hypoglycemia risk and risk factors, need for different interventions at varying points in time and contexts, and lack of consensus about how hypoglycemia is defined, measured, and recorded. Both interventional and non-interventional studies should be encouraged to use standard definitions of hypoglycemia and to ascertain/report hypoglycemia in all trials that enroll patients with diabetes. Healthcare providers should ask patients about their experience of hypoglycemia, how this hypoglycemia is detected and managed, and what events predated or precipitated its occurrence. This information, and glycemic data from patient devices and diabetes technologies, can then be incorporated into the electronic health record to facilitate hypoglycemia detection, management, and prevention strategies. Finally, both clinical guidelines and quality/accountability measures need to reflect the importance of hypoglycemia in the management of diabetes and to consider patients' treatment goals and anticipated benefits and harms of treatment [102] .
Patient-centered diabetes care is predicated on identifying and promoting safe and effective treatment strategies that minimize patient burden, improve quality of life, and reduce risks of both immediate and long-term complications. Addressing hypoglycemia by leveraging advances in diabetes technologies, patient engagement, multidisciplinary team-based care, and alignment of reimbursement and policy decisions is an essential part of this effort.
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